Derangement of immune responses by myeloid suppressor cells - PubMed (original) (raw)
Review
Derangement of immune responses by myeloid suppressor cells
Paolo Serafini et al. Cancer Immunol Immunother. 2004 Feb.
Abstract
In tumor-bearing mice and cancer patients, tumor progression is often associated with altered hematopoiesis leading to the accumulation of myeloid cells. Extensive studies in preclinical models indicate that these cells share the CD11b and the Gr-1 markers, possess a mixed mature-immature myeloid phenotype, and are responsible for the induction of T-cell dysfunctions, both tumor-specific and nonspecific. Moreover, CD11b(+)Gr-1(+) myeloid cells are described under different unrelated situations associated with temporary impairment of the T-lymphocyte reactivity. This review examines recent findings on the nature, properties, and mechanisms of action of these myeloid suppressor cells (MSCs).
Similar articles
- Tumor-induced immune dysfunctions caused by myeloid suppressor cells.
Bronte V, Serafini P, Apolloni E, Zanovello P. Bronte V, et al. J Immunother. 2001 Nov-Dec;24(6):431-46. doi: 10.1097/00002371-200111000-00001. J Immunother. 2001. PMID: 11759067 Review. - Immature myeloid cells and cancer-associated immune suppression.
Kusmartsev S, Gabrilovich DI. Kusmartsev S, et al. Cancer Immunol Immunother. 2002 Aug;51(6):293-8. doi: 10.1007/s00262-002-0280-8. Epub 2002 Apr 24. Cancer Immunol Immunother. 2002. PMID: 12111117 Free PMC article. Review. - Myeloid-derived suppressor cell heterogeneity and subset definition.
Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Peranzoni E, et al. Curr Opin Immunol. 2010 Apr;22(2):238-44. doi: 10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. Curr Opin Immunol. 2010. PMID: 20171075 Review. - Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S, Bronte V, Mandruzzato S. Solito S, et al. J Leukoc Biol. 2011 Jul;90(1):31-6. doi: 10.1189/jlb.0111021. Epub 2011 Apr 12. J Leukoc Biol. 2011. PMID: 21486906 Review. - CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells.
Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. Yang R, et al. Cancer Res. 2006 Jul 1;66(13):6807-15. doi: 10.1158/0008-5472.CAN-05-3755. Cancer Res. 2006. PMID: 16818658
Cited by
- Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Tarhini AA, et al. J Immunother. 2012 Nov-Dec;35(9):702-10. doi: 10.1097/CJI.0b013e318272569b. J Immunother. 2012. PMID: 23090079 Free PMC article. - Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.
Kennedy GT, Judy BF, Bhojnagarwala P, Moon EK, Fridlender ZG, Albelda SM, Singhal S. Kennedy GT, et al. Immunol Lett. 2015 Jul;166(1):28-35. doi: 10.1016/j.imlet.2015.05.009. Epub 2015 May 18. Immunol Lett. 2015. PMID: 25999306 Free PMC article. - Current perspectives in prostate cancer vaccines.
Arlen PM, Gulley JL. Arlen PM, et al. Anticancer Agents Med Chem. 2009 Dec;9(10):1052-7. doi: 10.2174/187152009789735062. Anticancer Agents Med Chem. 2009. PMID: 19719454 Free PMC article. Review. - Targeting Metalloenzymes for Therapeutic Intervention.
Chen AY, Adamek RN, Dick BL, Credille CV, Morrison CN, Cohen SM. Chen AY, et al. Chem Rev. 2019 Jan 23;119(2):1323-1455. doi: 10.1021/acs.chemrev.8b00201. Epub 2018 Sep 7. Chem Rev. 2019. PMID: 30192523 Free PMC article. Review.
References
- Ahlers Proc Natl Acad Sci U S A. 2002;99:13020. - PubMed
- al Microb Pathog. 1992;12:267. - PubMed
- Albina J Surg Res. 1993;55:97. - PubMed
- Almand Clin Cancer Res. 2000;6:1755. - PubMed
- Almand J Immunol. 2001;166:678. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials